Ranbaxy Laboratories Limited ("Ranbaxy") was an Indian multinational generic-drug manufacturer incorporated in 1961, with origins dating to a 1937 pharmaceutical distribution business. Its headquarters were in Gurgaon, Haryana, India. Ranbaxy went public in 1973 and was listed on the BSE, NSE and Luxembourg exchange. Daiichi Sankyo acquired a controlling stake (~63.9%) in 2008 for roughly US$4.6 billion. In April 2014 Sun Pharmaceutical Industries agreed to acquire Ranbaxy in an all-share deal valued around US$4 billion; the merger completed in 2015, Ranbaxy was delisted, and the brand was retired. Ranbaxy therefore no longer operates as an independent company — it is now part of Sun Pharma (NSE/BSE: SUNPHARMA).
Products and operations. Ranbaxy developed, manufactured and marketed generic and branded-generic pharmaceuticals, plus active pharmaceutical ingredients (APIs) and intermediates. Therapeutic coverage included anti-infectives, cardiovascular, CNS, urology, metabolic disorders, inflammatory/respiratory and dermatological products; the company also marketed differentiated products such as Absorica (isotretinoin). It claimed a footprint across roughly 49 countries, manufacturing in about 11 countries, and sales in 125+ markets, including US subsidiaries Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc. and Ohm Laboratories. Its 2012 annual report cited over 14,600 employees globally; standalone FY2012 net sales were about ₹61.1 billion. Ranbaxy's later years were dominated by US FDA manufacturing-compliance problems, including a 2013 US guilty plea and US$500 million penalty over adulterated drugs — no longer current facts, but central to its history.
Patent-litigation posture. Ranbaxy appears once in the tracked data, as a defendant and zero times as plaintiff — consistent with an operating company defending Hatch-Waxman ANDA litigation rather than an NPE. The single tracked suit was filed in the U.S. District Court for the District of New Jersey, not a plaintiff-friendly venue such as the Eastern District of Texas.
Notable case. Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Limited et al. (D.N.J., filed 2014-07-15) followed Ranbaxy's Paragraph IV certification on ANDA No. 203351 for generic sodium oxybate (Xyrem); Jazz asserted several Orange Book patents. The parties settled in May 2016 on confidential terms, and Ranbaxy's related IPRs and counterclaims were terminated. Note that the case list here is limited to one appearance; older Ranbaxy patent disputes are not captured.